Creutzfeldt-Jakob disease (CJD)—a fatal neurodegenerative illness, is one
form of transmissible spongiform encephalopathies (TSE) affecting humans. The
suspected causal agent of these diseases is the prion—a proteinaceous infectious
particle. Designated as PrPSC, this infectious protein is unique in that it does
not contain nucleic acid, which is different from a virus, yet has the
capability of replication and being transmitted to other hosts. This capability
of transmission poses a major problem in that the detection of the disease
caused by this prion while the individual is in the incubation phase is not
currently possible. Hence the disease may be accidentally transmitted to another
individual through medical procedures—as seen in the case study presented.
Throughout the 20th century, various case studies evolved and were compiled
to form a sketchy descriptive pattern for Creutzfeldt-Jakob disease. However, as
time progressed, new forms of CJD emerged—usually as an epidemic, presenting
similar yet distinct prodromal and clinical patterns. Accumulation of data has
led to a finer delineation of symptomology and sub-type classification of the
disease. Yet a test to definitively show that the individual has the disease
during incubation is not currently available.
With different methods of
transmission and com
pletion of the incubation periods, various epidemics have
erupted. Those points in time have been reflected within the literature, e.g.
iatrogenic CJD through growth hormone (HgH). Current known forms of CJD are
sub-typed as sporadic (spontaneous), familial (genetic), new variant and
iatrogenic (acquired by accidental medical introduction).
Documentation of
the transmission of Creutzfeldt-Jakob disease through blood products and other
similar tissues is very limited. Currently, there are no cases found in the
literature reflecting the onset of the disease via immune gamma globulin (IgG)
treatment. One major reason for this may be due to the fact that even if the
disease is transmitted, the incubation period may span beyond an individual’s
lifespan. Therefore, the individual will die incubating the disease, never
entering the clinical phase.
Each of the different categories of the disease
presents various clinical and neuropathological symptoms and patterns at onset
and throughout the course of the disease. The prion strain, codon 129 and method
of infectivity (exposure) are contributing factors in the incubation period and
clinical presentation of Creutzfeldt-Jakob disease.
Prion strains present
various protein sizes which are currently described as type I-IV. Each type is
associated with a specific subtype of the disease, e.g. type I and II are
associated with sporadic Creutzfeldt-Jakob disease. Heterozygosity on codon 129
has shown to act as a protective barrier to the disease by prolonging the
incubation period or may prevent acceptance for transmission. Homozygosity on
codon 129, however, places an individual at a higher risk level for contraction,
produces a shorter incubation period and more severe symptomology and/or
pathology. Codon 129 may also affect the age for onset of the disease.
Currently, sporadic CJD (sCJD) is the most prevalent strain occurring in
humans, representing 80-85% of the reported cases of Creutzfeldt-Jakob disease.
Hypothetically, this particular strain occurs spontaneously, i.e. idiopathic,
and may be transmitted to other humans medically through use of tissue/blood
products/procedures.
Familial CJD (fCJD), however, may be genetically traced
through family lines. Various specific mutations on the prion gene (PRNP) create
a predisposition for family members as to the onset, course and severity of the
disease.
Knowledge of the symptoms and course of the disease has become more
urgent due to the recent epidemic of bovine spongiform encephalopathy (BSE) in
cattle in the United Kingdom and the link to new variant CJD (vCJD) in humans as
a possible species-barrier crossover. Since one possible link for transmission
is that of consumption of infected beef, a possible epidemic of vCJD may be seen
to emerge in the next few years. Another concern related to vCJD is the transfer
or transmission to another individual through tainted medical supplies, e.g.,
blood products, while the individual is in the incubation period or prodromal
phase of the disease.
Transmission of this type would be recognized or
categorized as iatrogenic, i.e. acquired from another source outside of the host
through tainted medical supplies/procedures. Normal or generally accepted
sterilization methods that destroy bacteria or viruses do not work on prions.
Inactivation of prions requires extremely rigorous methods that would destroy
tissues and many surgical instruments in the process. Individuals incubating any
of the previous forms of CJD may inadvertently transmit the disease through
blood/tissue donor products or through contamination of surgical instruments
during a surgical procedure. This is the final known form of Creutzfeldt-Jakob
disease and is dependent on the other forms of the disease for existence. The
course of the disease may be presented with a short or lengthy incubation period
depending on the method of transmission, i.e. centrally or peripherally.
To
further complicate the transmission of the disease, many of these products are
not held within an individual’s community but are processed as a batch and
become exported to other countries. Therefore, the possibility of transmission
through tissue products is not restricted to one specific region or population
due to economic globalization and interdependency.
This has been the case
and continues to be the case for the transmission being reported in various
areas of the world. The case study currently presented is one such incident
where the contaminated product was imported into the United States from Canada.
Through that product—tainted immune globulin gamma (IgG), transmission of
Creutzfeldt-Jakob disease occurred during peripheral medical procedures.
The
case has created numerous diagnoses, complications and confusion among those
involved. Resources available continue to be maximized to minimize the effects
that maintaining appointments and traveling have on the individual. Involvement
with the individual and the family will be continued until the diagnosis/results
are definitive and support or participation are no longer desired.
Purpose
This research project follows an individual through the
course of events surrounding the progression of a possible onset of iatrogenic
Creutzfeldt-Jakob disease transmitted through tainted immune gamma globulin
(IgG). The treating physician informed the individual about the infectivity
after several months of treatment. Approximately 6 years later, the individual
has begun to rapidly display symptoms of the disease.
The purpose of the
research is to:
· Provide a detailed account of the symptomology, duration
and severity displayed at onset and throughout the course of the disease
presented;
· Identify polymorphisms on codon 129 or PRNP mutations, if any;
and
· Extend or enhance the existing database of the disease through
differential diagnosis or actual iatrogenic CJD information.
Limitations
Information gathered in a case study is intense for a particular individual
which may place limitations on the extrapolation of findings to the general
population. There will be no other person exhibiting the exact symptoms with the
same degree of severity or duration. Comparative analysis will be made from
other peripheral iCJD cases since there is no known case for IgG iCJD.
Re-enactment of the research data obtained cannot be replicated. Researcher bias
may also be present though not intentional. Responses from the individual may
not reflect the true degree or level of symptomology being experienced, i.e. the
individual generally minimizes actual events occurring which may be out of
denial, fear, hope, optimism, etc.
Research Questions
Primary
Question
Question 1: If the case is iCJD, then what prodromal and clinical
patterns will evolve during the course of the disease?
Secondary Questions
Question 2: Will this case follow peripheral transmission patterns similar
to HgH or be unique in duration and degree of severity?
Question 3: If a
polymorphism has occurred on codon 129, what is encoded?
Question 4: Are any
mutations occurring in the open reading frame (ORF) of the prion protein gene
(PRNP)?
Question 5: What differential diagnoses will be ruled out?
Definition of Terms
Ataxia—refers to the physical movements of the
individual which are presented as a staggering gait and imbalance. This symptom
is one of the triad associated with Creutzfeldt-Jakob disease.
Bovine
Spongiform Encephalopathies (BSE): is a prion disease affecting the bovine or
cattle populations that has possibly crossed the species barrier to humans
through contaminated meat products and has been transmitted to zoo animals and
domestic cats via contaminated food products.
Codon 129: refers to the 129th
marker or segment of the prion gene and is encoded with methionine and valine.
This area may entail a non-disease causing polymorphism that may increase the
risk factors and symptomology of Creutzfeldt-Jakob disease.
Dementia: is one
of the three symptoms generally associated with Creutzfeldt-Jakob disease
characterized by cognitive decline (thought processes and memory) that is not
reversible.
Dura mater graft: is the membrane surrounding the brain that has
an enormous flexion and durability. This tissue is used to repair other areas of
body tissue, organs, or neurological damage. The membrane has been implicated as
one form of iatrogenic transmission.
Electroencephalogram (EEG): is a
procedure which measures the electrical impulses or activity within the brain.
In various forms of Creutzfeldt-Jakob disease, this activity is characterized by
a triphasic wave pattern, i.e. 3 pattern stages.
Endogenous: refers to the
process of the disease to be formed from within without external sources.
Sporadic CJD is such a form of disease.
Exogenous: is the antonym of
endogenous, i.e. the disease originated outside of the body and has gained
entrance (transmission). Iatrogenic and new variant CJD are examples that
reflect this process.
Familial Creutzfeldt-Jakob disease (fCJD): a form of
Creutzfeldt-Jakob disease that is inherited or has a genetic basis of origin.
Heterozygous: refers to the amino acids encoded on codon 129. The pair which
would be present is methionine and valine and may act as the human species
barrier for this disease. Also implicated with heterozygosity is increased
length of the incubation period and the decreased severity and duration of the
disease.
Homozygous: represents the polymorphism that has occurred at codon
129 and is presented as methionine/methionine pairing or valine/valine pairing
instead of the heterozygous pairing of methionine/valine. This change decreases
the incubation period and increases the risk, duration, and severity of the
disease.
Iatrogenic: is a condition which has been accidentally caused by
medical personnel or a medical procedure. Within the medical community, this
condition or act is sometimes referred to as “therapeutic misadventure.”
Iatrogenic Creutzfeldt-Jakob disease (iCJD): is the form of the disease
which has been caused by a medical procedure due to contaminated material or
equipment.
Immunoglobulin G (IgG): represents one of 5 different antibodies
manufactured by the body. This antibody protects or establishes a defense
against harmful bacterial, viral, and fungal agents. Also known as immune
globulin gamma.
Intraperitoneal: refers to the area within the peritoneum
cavity (abdominal cavity).
Lymphoreticular system (LRS) : includes the
spleen, lymph nodes, and tonsils. The system transports blood components used to
fight infections and diseases and has been associated with the clearing and
possible transporting of the prion protein.
Macrophage: refers to a
specialized cell that is capable of phagocytosis, i.e. to eat or destroy
microorganisms or other diseased or dead cells.
Methionine (Met): an amino
acid encoded on codon 129. If homozygous, then listed as Met/Met; if
heterozygous, listed as Met/Val.
Mutation: refers to the permanent change of
a codon on the prion gene (PRNP) that is disease related.
Myoclonus: is
characterized by spasms within a group of muscles. These spasms may occur
sparingly or frequently within the disease.
Phagocytosis: is a process that
a specialized cell initiates in removing a microorganisms, diseased, dead or
dying cell, or debris from an internal system within the body. The literal
translation from Greek is “to eat.”
Plaques: used in this context refers to
the neurological condition from the build-up seen within the various parts of
the brain due to the prion protein.
Prion: designates the term given to
proteinaceous infectious particle which is the primary disease causing-agent of
CJD. The term is pronounced pree-on.
PrPC: is the abbreviation given to the
cellular nonpathogenic prion isoform.
PrPSC: designates the pathogenic prion
isoform.
PRNP: refers to the prion gene.
Prodromal: is an element of
time which refers to the symptoms/characteristics of the disease that occur
prior to the clinical phase. Symptoms that commonly occur or are seen in the
general population are included in this phase, e.g. depression, forgetfulness or
irritability.
Species barrier: is a phenomenon that prevents or deters the
transmission of disease occurring in one species to another. In the case of CJD,
if a crossover does occur, then the length of incubation is seen to typically
increase and the areas of tissue in the brain affected also differ.
Sporadic
Creutzfeldt-Jakob disease (sCJD): the most common form of the disease that
occurs idiopathically, i.e. without a known cause.
Transmissible spongiform
encephalopathy (TSE): is the name given to the category of prion diseases
effecting animals and humans. The disease is capable of being transmitted within
the species, and destroys brain tissue which takes on the characteristic of a
natural sponge, i.e. full of holes.
Valine (Val): one of the amino acids
found on codon 129.
Variant Creutzfeldt-Jakob disease (vCJD): the form of
CJD associated with the species barrier crossover from BSE or mad cow disease
found in Europe. This form is also known as nvCJD or new variant CJD.
Primary Approach for Data Collection
A qualitative design using
observation, interviews with the individual and medical personnel involved, as
well as reviews and analysis of written reports/tests and literature was the
primary approach for data collection. The individual case study provided the
opportunity to find answers to questions or solutions to a problem since human
experiments involving CJD are unethical. This method provided a comprehensive,
detailed account of the progression/characteristics of the disease being
experienced. A compassionate outlet was provided for the individual in that
his/her concerns or fears were openly discussed and clarified. Therefore insight
into a thought process or emotional aspect that others with this disease may
also have experienced may be provided. Also, the individual may find relief or
comfort in talking and being heard. The data collected was analyzed according to
the previous established patterns displayed by other types of CJD, i.e. was a
relationship established. Implementing qualitative methodology in this case
study, took an individual’s specific concerns to larger social issues
surrounding concerns of medical risks associated with supplies and procedures
and identification of the characteristics/symptomology of the disease itself.
Selection of Research Population
The original research project did
not revolve around this individual even after the accidental discovery that CJD
had been transmitted many years ago. At that time, the individual displayed no
clinical signs of the disease and was relatively healthy. Within a few weeks,
the entire health related picture began to change.
A very complex scenario
began to emerge for everyone involved, as did uncertainty as to whether to even
approach what was being seen. I was skeptical due to the rarity of the disease,
the mimicking symptoms presented by other diseases, and the lack of specificity
of diagnostic tests. After careful deliberation with various professionals, the
decision was made to go forward following the course of this individual. The
disease could “not” be ruled out, but also could not be positively diagnosed
since this required postmortem brain tissue biopsy or premortem brain biopsy.
The later procedure placed this individual at risk. A final comment cemented the
course of the dissertation: regardless if this is iCJD or not, you will be
gathering information that will be important for disease identification. If you
choose not to proceed, the complete intricate package of information will be
lost…
Benefits Derived from Study
This case study of an individual with
possible onset of Creutzfeldt-Jakob disease via IgG has been done to provide:
· Beneficial information which expands or enhances the data base on the
disease since the information is rich in detail and may be an index case;
·
The interaction of factors at play within the disease which included incubation
period, method of transmission, codon 129 and the prodromal, clinical and
differential diagnostic characteristics of the disease; and
· An awareness
as to the risk factors of transmission which may have bearing on public health
policies.
Summary
The objective of the research was to determine if
the peripheral transmission of Creutzfeldt-Jakob disease via contaminated IgG
would follow the same or similar disease course characteristics as other types
of peripheral iatrogenic CJD cases. Research focused on the behavioral,
cognitive and motor functions in relation to those seen in various forms of CJD
at various stages of the disease—whether typical or atypical.
Medical
records, literature reviews and interviews/consultations with the individual and
medical personnel were made to gather and analyze data. All of the data was
compiled to determine whether the disease characteristics displayed indeed
followed the distinct patterns of the disease or if surprises waited around the
corner.